| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MOCS1 |
| Uniprot No | Q9NZB8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-636aa |
| 氨基酸序列 | MAARPLSRML RRLLRSSARS CSSGAPVTQP CPGESARAAS EEVSRRRQFL REHAAPFSAF LTDSFGRQHS YLRISLTEKC NLRCQYCMPE EGVPLTPKAN LLTTEEILTL ARLFVKEGID KIRLTGGEPL IRPDVVDIVA QLQRLEGLRT IGVTTNGINL ARLLPQLQKA GLSAINISLD TLVPAKFEFI VRRKGFHKVM EGIHKAIELG YNPVKVNCVV MRGLNEDELL DFAALTEGLP LDVRFIEYMP FDGNKWNFKK MVSYKEMLDT VRQQWPELEK VPEEESSTAK AFKIPGFQGQ ISFITSMSEH FCGTCNRLRI TADGNLKVCL FGNSEVSLRD HLRAGASEQE LLRIIGAAVG RKKRQHAGMF SISQMKNRPM ILIELFLMFP NSPPANPSIF SWDPLHVQGL RPRMSFSSQV ATLWKGCRVP QTPPLAQQRL GSGSFQRHYT SRADSDANSK CLSPGSWASA APSGPQLTSE QLTHVDSEGR AAMVDVGRKP DTERVAVASA VVLLGPVAFK LVQQNQLKKG DALVVAQLAG VQAAKVTSQL IPLCHHVALS HIQVQLELDS TRHAVKIQAS CRARGPTGVE MEALTSAAVA ALTLYDMCKA VSRDIVLEEI KLISKTGGQR GDFHRA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MOCS1重组蛋白的3篇参考文献(文献信息为模拟概括，实际引用需核实原文)：
---
1. **文献名称**: "Functional characterization of recombinant human MOCS1 protein in molybdenum cofactor biosynthesis"
**作者**: Smith A, et al.
**摘要**: 研究重组表达人源MOCS1蛋白在体外钼辅因子合成中的功能，证实其通过水解GTP生成前体物质，并解析其酶活性依赖的关键结构域。
2. **文献名称**: "Expression and purification of MOCS1A and MOCS1B isoforms: Implications for molybdenum cofactor deficiency therapy"
**作者**: Johnson R, et al.
**摘要**: 报道通过大肠杆菌系统成功表达并纯化MOCS1的两种剪接变体(MOCS1A和MOCS1B)，验证其相互作用及在钼辅因子修复中的潜在治疗应用。
3. **文献名称**: "Structural insights into the MOCS1-catalyzed step of molybdopterin biosynthesis"
**作者**: Lee C, et al.
**摘要**: 利用X射线晶体学解析重组MOCS1蛋白的三维结构，揭示其催化位点及与底物结合的分子机制，为遗传性钼辅因子缺乏症提供药物设计靶点。
---
**说明**：以上文献内容为示例性概括，实际研究中需通过PubMed或Web of Science等数据库检索最新文献，并核对作者、标题及摘要准确性。建议使用关键词“MOCS1 recombinant protein”或“MOCS1 expression”进行检索。
**Background of MOCS1 Recombinant Protein**
MOCS1 (Molybdenum Cofactor Synthesis 1) is a critical enzyme involved in the biosynthesis of the molybdenum cofactor (MoCo), an essential component required for the activity of molybdenum-dependent enzymes such as sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. MoCo synthesis is a highly conserved pathway across eukaryotes, and MOCS1 plays a dual role in this process. The *MOCS1* gene encodes two distinct enzymes, MOCS1A and MOCS1B, through a unique bicistronic mechanism. MOCS1A catalyzes the conversion of GTP into precursor Z, while MOCS1B, a molybdopterin synthase, facilitates the insertion of molybdenum into the matured cofactor.
Deficiencies in MOCS1 function lead to MoCo deficiency, a rare autosomal recessive disorder characterized by severe neurological symptoms, seizures, and neonatal lethality due to the loss of sulfite oxidase activity. Current therapeutic options are limited, making recombinant MOCS1 protein a focal point for research into enzyme replacement therapies or gene-editing strategies.
Recombinant MOCS1 protein is typically produced using heterologous expression systems (e.g., *E. coli* or mammalian cell cultures) to ensure proper folding and post-translational modifications. Its production enables structural and functional studies, including elucidating catalytic mechanisms, substrate interactions, and mutational impacts linked to disease. Challenges in its development include maintaining protein stability, achieving correct post-translational modifications, and ensuring functional activity in vivo.
Recent advances in protein engineering and delivery systems, such as nanoparticle carriers or viral vectors, have enhanced the potential for MOCS1 recombinant protein to serve as a therapeutic agent. Additionally, it serves as a tool for high-throughput drug screening to identify small molecules that could stabilize or enhance residual MoCo synthesis in patients. Understanding MOCS1’s biochemistry and developing its recombinant form remain vital for addressing MoCo deficiency and related metabolic disorders.
×
